Brenda M. Sandmaier, M.D., Named ASTCT 2022-2023 President
26 avr. 2022 09h00 HE
|
American Society for Transplantation and Cellular Therapy
CHICAGO, April 26, 2022 (GLOBE NEWSWIRE) -- American Society for Transplantation and Cellular Therapy (ASTCT) announced Brenda M. Sandmaier, M.D., as the ASTCT President in 2022-2023. Dr....
Stem Cell Global Market Growth Opportunities: A $18.51 Billion Market in 2026, Registering CAGR of 9.8%
15 avr. 2022 04h18 HE
|
Research and Markets
Dublin, April 15, 2022 (GLOBE NEWSWIRE) -- The "Stem Cell Global Market Report 2022, By Source, By Product Type, By Application" report has been added to ResearchAndMarkets.com's offering.The global...
Global $36 Billion Stem Cell Markets Analysis & Forecasts, 2015-2020, 2020-2025F, 2030F
02 févr. 2022 04h03 HE
|
Research and Markets
Dublin, Feb. 02, 2022 (GLOBE NEWSWIRE) -- The "Stem Cell Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering. The global stem...
Karmanos Cancer Institute partners with The Toledo Clinic to establish a new cancer center in Northwest Ohio
06 avr. 2021 14h56 HE
|
Karmanos Cancer Institute
Detroit, Michigan and Toledo, Ohio, April 06, 2021 (GLOBE NEWSWIRE) -- DETROIT, Mich. – The Barbara Ann Karmanos Cancer Institute is pleased to announce that it has entered into a partnership with...
Hemoglobinopathies Market To Reach USD 13.68 Billion By 2026 | Reports And Data
07 nov. 2019 12h06 HE
|
Reports and Data
New York, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Insufficient healthcare infrastructure and low levels of disease diagnosis and treatments, rising prevalence of hemoglobin disorders such as Sickle Cell...
Actinium Announces New Clinical Trial to Study Effect of Actimab-A on Minimal Residual Disease in Postremission AML Patients
28 juin 2018 08h00 HE
|
Actinium Pharmaceuticals
Minimal Residual Disease is increasingly recognized as a primary driver of high AML relapse rate highlighting need for improved consolidation therapies Webcast to be held on July 10, 2018 at 8:00 AM...
Actinium Pharmaceuticals Announces Dosing of 38th Patient and 25 Percent Enrollment in Iomab-B Pivotal SIERRA Trial
26 juin 2018 08h00 HE
|
Actinium Pharmaceuticals
Iomab-B remains the only targeted conditioning treatment in clinical trials with the potential to increase access to and improve outcomes of bone marrow transplant NEW YORK, June 26,...
Actinium Provides Update from Society of Nuclear Medicine and Molecular Imaging Annual Meeting
25 juin 2018 16h15 HE
|
Actinium Pharmaceuticals
Two Nuclear Medicine focused advisory boards have been formed to provide expertise and strategic guidance to Actinium Meeting with Iomab-B and Actimab investigators to be held to provide trial...
Actinium Pharmaceuticals Announces Treatment of First Patient in Novel Combination Trial of Actimab-A Plus CLAG-M
13 juin 2018 08h00 HE
|
Actinium Pharmaceuticals
- Trial supports Actinium’s strategic expansion of its CD33 program into novel combinations that can lead to increased use of bone marrow transplants and expand the addressable patient population for...
Actinium Pharmaceuticals to Present at 19th Annual Bio€quity Europe Conference in Ghent, Belgium
08 mai 2018 07h30 HE
|
Actinium Pharmaceuticals
- Management to conduct business development and investor focused meetings at the conference NEW YORK, May 08, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM)...